Dr Hemmel Amrania

Dr. Hemmel Amrania serves as the Chief Executive Officer and is a distinguished medical research scientist focused on transforming cancer care. Recognizing the urgent need for reliable predictive tests that are both timely and affordable, Dr. Amrania has been instrumental in developing innovative approaches to cancer risk assessment and management. He initiated a significant shift in the field by combining infrared multi-spectral imaging (spectrometry) with artificial intelligence, a method that not only speeds up the process but also reduces costs substantially. This advancement helps eliminate the subjectivity typically associated with traditional biomarker analysis, thereby facilitating more informed treatment decisions. Dr. Amrania’s work is particularly crucial for clinicians and patients, as it addresses the pervasive fear of cancer recurrence and aids in determining the necessity of chemotherapy and other treatments. His efforts have opened up new possibilities for accessible and efficient decision-making in cancer treatment, significantly improving patient outcomes.